CheckMyRecalls

Ascend Laboratories, LLC recalls Dabigatran etexilate Capsules

Published
29 Jul 2026
Units affected
2 products
Agency
FDA
Country
United States

The hazard

Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.

Classification: Class III — this product is unlikely to cause health problems but breaks FDA rules (for example labeling).

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Dabigatran etexilate Capsules, 150 mg, 20-count carton (2x10), Rx only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-7255-10.

Dabigatran etexilate Capsules, 110 mg, 60-count carton (6x10), Rx Only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-7254-68.

Brand / company
Ascend Laboratories, LLC
Codes / lots
Lot: 25141584, Exp 4/30/2027. | Lot: 25141707, Exp 4/30/2027.
Distribution
USA Nationwide
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 29 Jul 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.